within Pharmacolibrary.Drugs.ATC.A;

model A05AX02
  extends Pharmacokinetic.Models.PK_1C_enteral(
    weight         = 70,
    F              = 0.3,
    Cl             = 0.00016666666666666666,
    adminDuration  = 600,
    adminMass      = 300 / 1000000,   // mg → kg
    adminCount     = 1,
    Vd             = 0.0002,
    Cmin           = 0.001,
    Cmax           = 0.01,
    Ctox_peak      = 0.02,
    Ctox_trough    = 0.01,
    ka             = 0.0016666666666666668,
    Tlag           = 600
  );

  annotation (Documentation(
    info       = "<html><body><table><tr><td>Drug:</td><td>A05AX02</td></tr><td>route:</td><td>oral</td></tr><tr><td>n-compartments</td><td>1</td></tr></table><p>Hymecromone (also known as 4-methylumbelliferone) is a coumarin derivative used primarily as a choleretic agent to stimulate bile secretion and flow. It has also been explored in research for its potential antitumor, antispasmodic, and antithrombotic activities. It is approved and used in some countries for the treatment of biliary dyskinesia and other conditions related to bile flow, but is not universally approved worldwide.</p><h4>Pharmacokinetics</h4><p>Estimated pharmacokinetic parameters for adult healthy individuals, as published explicit human PK data are limited.</p><h4>References</h4><ol><li><p>Garrett, ER, et al., &amp; Cerda, JJ (1993). Pharmacokinetics and bioavailabilities of hymecromone in human volunteers. <i>Biopharmaceutics &amp; drug disposition</i> 14(1) 13–39. DOI:<a href=&quot;https://doi.org/10.1002/bdd.2510140103&quot;>10.1002/bdd.2510140103</a>  PUBMED:<a href=&quot;https://pubmed.ncbi.nlm.nih.gov/8427942/&quot;>https://pubmed.ncbi.nlm.nih.gov/8427942</a></p></li><li><p>Kuipers, HF, et al., &amp; Bollyky, PL (2016). The pharmacokinetics and dosing of oral 4-methylumbelliferone for inhibition of hyaluronan synthesis in mice. <i>Clinical and experimental immunology</i> 185(3) 372–381. DOI:<a href=&quot;https://doi.org/10.1111/cei.12815&quot;>10.1111/cei.12815</a>  PUBMED:<a href=&quot;https://pubmed.ncbi.nlm.nih.gov/27218304/&quot;>https://pubmed.ncbi.nlm.nih.gov/27218304</a></p></li><li><p>Kohli, AG, et al., &amp; Szoka, FC (2014). Improving the distribution of Doxil® in the tumor matrix by depletion of tumor hyaluronan. <i>Journal of controlled release : official journal of the Controlled Release Society</i> 191 105–114. DOI:<a href=&quot;https://doi.org/10.1016/j.jconrel.2014.05.019&quot;>10.1016/j.jconrel.2014.05.019</a>  PUBMED:<a href=&quot;https://pubmed.ncbi.nlm.nih.gov/24852095/&quot;>https://pubmed.ncbi.nlm.nih.gov/24852095</a></p></li></ol></body></html>",
    revisions  = "<html><body><ul><li>06/2025 initial model generated by LLM gpt-4.1 from general data</li></ul></body></html>"
  ));
end A05AX02;
